PharmaResearch Products, Registration Approval of Automatic Drug Injector ‘Rejumate Injector’ > News

PR Center

A biopharmaceutical firm realizing regenerative medicine

News

News

PharmaResearch Products, Registration Approval of Automatic Drug Injec…

페이지 정보

Date21-02-03 14:53 Number of views216

본문

[Press Release]

PharmaResearch Products, Registration Approval of Automatic Drug Injector ‘Rejumate Injector’

 

PharmaResearch Products (CEO Kim Shin-Kyu and Kang Ki-Seock) announced on the 15th that the medical device ‘Rejumate Injector’, which automatically injects drugs into the skin, will complete the MFDS (Korean FDA)'s registration and start selling in October.

 

Rejumate Injector’ is a compound word of REJURAN and MATE, and plans to strengthen its brand position in the market through synergy with Rejuran, the representative product of the PharmaResearch Product.

 

The ‘Rejumate Injector’ is a medical device that automatically injects drugs into the skin using 9-pin 34G thin sterilized needle, and can choose two needle lengths depending on the thickness of the skin.

 

The advantage of this is that the procedure causes less pain than a normal syringe and the precise amount of medication can be injected.

 

In particular, it was manufactured as a wireless product considering the convenience of users, and depending on the type of drug, it is easy to select functions with simple operation.

 

Park Hyun-Jun, director of Apgujeong Maylin Clinic, who participated in the development, said of Rejumate, "Three key points will increase patients' needs and satisfaction, including the fact that there is little drug loss, causes no bruising from disrupting blood vessels, and the pain is lessened by 50 percent."

 

Inquiries about Rejumate Injector products can be made via phone (031-8039-1499).